CTLA4 and hypophysitis: On the contrary, the ipilimumab–induced incidence of hypophysitis was 0–17%, as reported by the clinical data obtained from the studies on ICI–induced hypophysitis for CTLA–4 [48,66], while that for tremelimumab (phase I and randomized clinical trial results) was 0.4–5% [66,67].